During acute lung inflammation, the airspaces are invaded by circulating neutrophils. These may then injure tissues through the release of elastase. Different natural specific inhibitors such as α1-PI, SLPI and elafin, are nonetheless able to counteract the enzymatic activity of elastase. The present study was undertaken to assess the role of these different inhibitors in the intrinsic anti-elastase barrier during LPS-induced lung inflammation in mice. Upon intranasal administration of LPS to mice, the anti-elastase activity recovered from bronchoalveolar lavage fluids (BALF) increases progressively up to 48 h (7-fold) and returns to the basal level within 72 h.
Introduction
More than a century ago, Metchnikoff recognized that neutrophils can create autologous injury to lung tissue. Since then, a large number of studies have confirmed that neutrophils play a major role in the onset and progression of acute lung injury in both the clinical setting and experimental animal models (1) (2) (3) (4) . In human lung inflammation such as in the acute respiratory distress syndrome (ARDS), the burden of neutrophils constitutes the main threat (5, 6) . Neutrophils are mostly harmful through the release of their serine proteinases particularly elastase (2, 7, 8) . Human leukocyte elastase exerts a strong tissue-damaging activity by hydrolyzing most extracellular matrix components such as elastin, fibronectin, proteoglycan, and collagen, and also by affecting the integrity of the endo-epithelial barrier (9) (10) (11) . Indeed, increased elastase activity has been found in the bronchoalveolar lavage fluids (BALF) in patients with ARDS (12) . This prompted studies which showed that the use of structurally different elastase inhibitors was beneficial in models of acute lung inflammation (13) . Indeed, the body produces different natural specific inhibitors to counteract the biological destructive activity of elastase (14, 15) . In lungs, one can consider two groups (16) , the early or alarm inhibitors such as the secretory leukocyte proteinase inhibitor (SLPI) and elafin, and the secondary or acute-phase inhibitors such as α1-proteinase inhibitor (α1-PI). Interestingly, the levels of α1-PI, SLPI and elafin, are augmented in ARDS (17) . The present study was undertaken to assess the role of these different inhibitors in the intrinsic anti-elastase barrier during LPS-induced lung inflammation in mice.
Materials and Methods
administration of the antineoplastic agent vinblastine (5 mg/kg). At the time of LPS administration, neutrophils were absent from the circulating blood.
3-LPS administration and collection of bronchoalveolar lavage fluids (BALF)
LPS dissolved in saline was administered intranasally (i.n, 330 µg/kg of body weight). Mice were slightly anesthetized with diethyl ether and received 50 µl of the LPS solution directly into their nostrils. At different time intervals, mice were euthanized by an i.p. administration of a lethal dose of pentobarbital sodium (12 mg/mouse). Tracheas were cannulated, and lungs were washed eight times with 0.5 ml of PBS to provide 4 ml. Cell free-BALF obtained after centrifugation (300 g for 15 min) were stored frozen at -20°C. In some experiments, DNase was given i.n. to mice (500 or 2000 U per animal), 3 hours before BALF collections.
4-Preparation of crude mouse leukocyte elastase
In order to prepare mouse leukocyte elastase, mice were challenged with LPS (330 µg/kg) and BALF were performed 24 hours later. The whole cell population of the BALF which routinely contains 90% of neutrophils was washed once with PBS, resuspended in PBS (5 X 10 6 cells/ml), preincubated for 5 min with 5 µg/ml cytochalasin B and then activated with 1µM fMLP. Cell degranulation was allowed to proceed for 10 min and supernatants were recovered after centrifugation at 300 g for 15 min. The elastase activity present in the medium was determined using the specific synthetic substrate N-methoxysuccinyl-Ala-Ala-Pro-Val pNitroanilide (1 mM, final concentration). Hydrolysis of this substrate was monitored following the optical density at 410 nm.
5-Measurement of anti-elastase activity in BALF
The anti-elastase activity contained in total BALF or BALF chromatography fractions was evaluated spectrophotometrically by following the elastase-mediated hydrolysis of N-methoxysuccinyl-Ala-Ala-Pro-Val pNitroanilide at 410 nm. Total BALF or BALF chromatography fractions were incubated with elastase (8 nM) for 5 minutes at 37°C in 0.5 ml of PBS with BSA 0.02% (pH 7.4) before addition of the substrate (1 mM). For each sample, an activity-volume curve was established and the volume (V) corresponding to 50% inhibition of elastase activity was calculated from the curve.
The volume needed to inhibit 1 µM elastase was extrapolated and considered to contain 1 unit of anti-elastase activity. In some experiments, samples were preincubated with DNase (200 U/ml) for 15 min at 37°C before testing their elastase inhibitory activity.
6-Analysis of SLPI specific mRNA
Lungs from control and RB6-8C5-treated mice were collected 48 h after LPS-induced acute lung inflammation, frozen in liquid nitrogen and RNA was isolated using the Bands were visualized by direct fluorescence on a "Storm phosphoimager"
(Molecular Dynamics, Amersham Pharmacia Biotech). Densitometry was carried out using the ImageQuant software and signal intensities were determined for SLPI and GAPDH bands.
7-SDS-PAGE and immunoblot analysis of α1-PI
Cell-free BALF were incubated with Laemmli's PAGE sample buffer (containing 2% SDS and no reducing agent) for 15 min at 100°C. Aliquots (30 µl) were applied to 10% polyacrylamide slab gel and electrophoresis carried out. Proteins were then electrotransferred to a nitrocellulose membrane and the α1-PI band immunoprobed with a 1:500 dilution of a rabbit specific antibody followed by a 1:10,000 dilution of a donkey anti-rabbit IgG antibody conjugated to horseradish peroxidase. Immunoblots were developed by ECL kit (Amersham Life Sciens, Amersham, UK).
8-Ultrafiltration
Each individual BALF was ultrafiltrated using Centricon filter devices equiped with a YM-100 (molecular size cut-off: 100 Kda) membrane and centrifuged at 1000 g. Anti-elastase activity was then measured in both the retentate and the filtrate. Aliquots (40 µl) were then subjected to electrophoresis on a 1% agarose slab gel containing 0.5 µg/ml ethidium bromide. Gel photographs were taken after amplification with ultra-Lum system (Ultra-Lum, CA) under ultraviolet light. A 1 kbp DNA ladder was used as standard.
After transfer to a nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) and baking at 80°C for 1 hr for optimal DNA binding, the membrane was immunoprobed with a 1:1,00 dilution of an anti-human neutrophil elastase rabbit specific antibody followed by a 1:10,000 dilution of a donkey anti-rabbit IgG antibody conjugated to horseradish peroxidase. Immunoblots were developed by ECL kit (Amersham Life Sciences, Amersham, UK).
11-Human studies
BALF were collected from 9 mechanically ventilated patients with acute lung injury and processed as previously described (21) . BALF analysis revealed a prominent neutrophilia. None of the BALF were infected as assessed by bacterial culture. The local ethical committee of Paris-Bichat University Hospital approved the study protocol.
12-Statistical analysis
All results are expressed as means ± sem. Differences between the data were analyzed by Student's unpaired t test. A p value <0.05 was considered significant.
Results
1-Anti-elastase activity increases in BALF after LPS-induced acute lung inflammation.
We have previously shown that the i.n. administration of LPS (330 µg/kg) induces neutrophil recruitment and increases vascular permeability in mice (22, 23) . During the course of the latter experiments, we observed a progressive increase of the BALF anti-elastase activity which peaked at 48 hr (tested against a crude preparation of murine elastase) (Fig. 1A) . At that time point, the magnitude of the increase was 7-fold that of the basal level. An inhibitory activity of BALF was also observed against human neutrophil elastase and cathepsin G (data not shown), showing that inhibitors present in BALF are active against several serine proteinases. However, throughout the following experiments, the BALF anti-proteinase activity was tested against purified human elastase.
2-Relationship between the anti-elastase activity and the presence of neutrophils.
Interestingly, the variation of the anti-elastase activity follows exactly the kinetic of neutrophil migration into the airspaces as observed in previous experiments (22) . As shown in Fig. 1B , a significant correlation was observed between neutrophil numbers and the anti-elastase activity in BALF. In order to assess the relationship between neutrophils and anti-elastase activity, mice were depleted of neutrophils by a pretreatment with an anti-granulocyte antibody (RB6-8C5), before the i.n.
administration of LPS. Under these experimental conditions, the increase of antielastase activity was almost totally abolished. It is of note that the used antibody is largely specific for granulocytic cells although low levels of Ly-6G, the targeted epitope, are expressed on dendritic cells (24) , antigen-presenting cells (25) , and macrophages (26) . To confirm our finding, mice were pretreated with another neutrophil-depleting agent, vinblastine, 96 h before LPS administration. As for mice treated with RB6-8C5, there was only a small increase in the anti-elastase activity 48 h after LPS administration (Fig. 2) . It is noteworthy that the anti-elastase activity 3-Role of α1-PI and SLPI
We have previously shown that the increase of vascular permeability is of the same magnitude at 48 h for both normal or neutropenic mice (23) . We therefore hypothesized that the increase in anti-elastase activity associated with neutrophilia was due not to a molecule originating from passive transfer from the blood compartment, but instead from the inflamed lungs-either from inflammatory cells or lung structural cells. Two antiproteinase candidates were thus considered, SLPI and elafin, since their human homologues are both produced by macrophages (27) , neutrophils (28) and also by epithelial cells upon activation by two early inflammatory cytokines, TNF-α and IL-1β (29) . The archetypal elastase inhibitor, α1-PI was also a possible candidate since it is synthesized by LPS-activated alveolar macrophages (30) and lung epithelial cells (29, (31) (32) (33) and more importantly in the present context, by neutrophils (34).
Since murine elafin has not yet been identified, we analyzed the potential role of both SLPI and α1-PI. Interestingly, although mice SLPI mRNA was easily detected in lung extracts, it is obvious from Fig. 3 that its expression was not significantly changed in both normal and neutropenic mice. We then analyzed the potential contribution of α1-PI to BALF anti-elastase activity. Nadziejko et al., (35) and us (not shown) have found that anti-elastase activities of human SLPI and human elafin, but not of human α1-PI, were resistant to hexadecyltrimethyl ammonium bromide (HTAB) treatments.
Incubation of BALF with the above cationic detergent abolished its anti-elastase activity, suggesting a participation of α1-PI in this process. The presence of the latter in BALF collected from control mice 48 h after LPS was thus checked by western blot analysis and was found to be increased compared to basal levels (Fig. 4) . This result indicated that α1-PI participated in the increase of the anti-elastase activity of BALF.
Nonetheless, specific α1-PI mRNA were not detected in extracts of whole lungs collected from mice under any experimental conditions (data not shown), suggesting that the protein originated most probably from plasma exudation due to the increase of vascular permeability which occurs indifferently in control and neutropenic animals (23), and not from a synthesis by recruited neutrophils. Confirming this, western blot analysis also revealed that the increased amounts of recovered α1-PI were identical whether mice were neutropenic or not (Fig. 4) . As a whole, these data suggest that α1-PI probably plays a role (see Fig 2 in Experiments were performed to characterize the unknown molecule(s) with an apparent molecular weight higher than 100 kDa. BALF from 20 LPS-challenged control mice were pooled, concentrated, subjected to gel filtration, and fractions were analysed for their absorbance and anti-elastase activity. As shown in Fig. 5 , a first peak (fractions 45 to 50) corresponding to a Mr of 600 kDa was detected, followed by a second peak of high activity (fractions 79 to 88) corresponding to a Mr of 50 kDa.
When BALF from neutropenic mice were processed in a similar fashion, only the 50 kDa peak was present (data not shown). Fractions 43 to 55 (E1) and fractions 78 to 94 (E2) from LPS-challenged control mice were pooled and concentrated separately. The determination of the protein content (Bradford method) indicated that E1 contained little proteinaceous material compared to E2, i.e. 540 µg and 11,120 µg, respectively, although the absorbance for each peak was similar (Fig. 5) .
5-Anti-elastase activity and DNA.
The discrepancy between absorption at 280 nm and the protein content of E1 concentrate, led us to run an absorption spectrum of the material. We observed that the absorption was higher at 260 nm than at 280 nm, suggesting the presence of nucleic acid material. An agarose slab gel electrophoresis and ethidium bromide staining revealed the presence of large amount of DNA in the E1 concentrate of BALF from 48 hr-LPS-challenged control mice compared to the E1 concentrate of BALF from 48 hr-LPS-challenged neutropenic mice (Fig. 6A ). In addition, preincubation of E1 with DNase (200 U/ml for 15 min at 37°C) led to the complete disappearance of the material. Since formation of complexes between DNA and human leukocyte elastase has been reported (36), we investigated the interaction between these two molecules. As shown in Fig. 6B , immunoblot analysis revealed that the migration profile of purified human elastase depended on whether it was incubated or not with the E1 concentrate from LPS-challenged control mice. The confirmation of the presence of a complex was shown by the addition of DNase which restored the migration profile of elastase.
As DNA not only binds elastase but also impairs its enzymatic activity (36), we hypothesized that most of the anti-elastase activity observed in E1 was due to DNA.
As shown in Fig. 7 , the anti-elastase activity in E1 was 20% of that of the control when DNA was destroyed upon DNase treatment. As a control, we verified that RNase treatment of the same sample was devoid of significant effect. We also purified genomic DNA from mouse tail and showed that it inhibited elastase (data not shown).
6-Effect of DNase in LPS-induced lung inflammation in vivo
To confirm that DNA accounted for most of the anti-elastase activity present in the BALF during acute lung inflammation, BALF from 48 hr-LPS-challenged control mice were pre-incubated with DNase prior to test their anti-elastase activity. Profiles of inhibition were similar to those observed with the E1 concentrate depicted in Fig. 7 , i.e. around 75% inhibition with DNase and no significant difference with RNase (data not shown). It is of note that DNase may impair the inhibitory capacity of α1-PI towards purified elastase activity, although this effect was reported to be limited to low concentrations of α1-PI (37) . To check this possibility, we assessed the antielastase activity in BALF of LPS-challenged neutropenic mice lacking DNA (but containing the same amount of α1-Pi, see Fig 4) . We found that whether BALF was treated or not with DNAse, the anti-elastase activity was similar (1.01 ± 0.39 and 0.89 ± 0.42 (means ± sem; n = 4) respectively), therefore ruling out an effect of DNase on α1-PI under our in vivo experimental conditions. Furthermore, i.n. administration of DNase also reduced the the antiproteinase activity recovered from inflamed lungs. Indeed, two different doses of DNase were administered to LPS-challenged mice, 45 hours post-LPS (i. e., 3 h before performing the lavage). As shown in Fig. 8 , DNase at 500 U/mouse and 2000 U/mouse displayed a similar inhibition of around 60% (n=3). This lack of difference between 500 and 2000 U DNase/mouse, indicates that, at these doses, DNA was totally hydrolyzed and consequently that the remaining 40% anti-elastase activity was most probably due the other elastase inhibitors such as SLPI and α1-PI.
7-Human studies
BALF from 9 patients suffering from ALI were first concentrated 10 times by ultrafiltration through a membrane with a cut-off of 100 kDa and the anti-elastase activities of the concentrates were analyzed. Agarose gel electrophoresis and ethidium bromide staining indicated that 6 out of 9 concentrates contained DNA material (data not shown). Interestingly, these 6 concentrates displayed an antielastase activity which was reduced upon incubation with 200 U/ml DNase for 15 min at 37°C (Fig. 9 ).
Discussion
Elastase is stored as an active enzyme in the neutrophil azurophil granules with two other serine proteinases, namely cathepsin G and proteinase 3. All three enzymes may be released extracellularly during the process of phagocytosis when neutrophils encounter microorganisms, and also when neutrophils accumulate at high density and lyse (2, 7, 8) . The ability of these different serine proteinases to injure lung tissues, necessitates a tight control of their enzymatic activities. The present data
show that during experimental acute lung inflammation in mice, the anti-proteinase barrier of the airways i) varies with the presence of neutrophils, and ii) is in part constituted of free DNA.
One of the surprising facts emerging from the present study is that DNA represents a quite large proportion of the anti-elastase barrier in mice with neutrophilic inflammation. Treatment of BALF of these mice with DNase allowed us to estimate its contribution at around 75% of the total. This was a surprising finding since the most important elastase inhibitors were thought to be SLPI, α1-PI, and elafin.
Nonetheless, the question remains as to whether the present experimental approach is a true modeling of an inflammatory human lung disease. Our present study confirms that DNA material is indeed present in the airspaces of ALI patients, and
participates (although in a variable and lower proportion than in mice) in the antiproteinase barrier activity.
The presence of DNA in the airways has been recognized for a long time in different lung pathologies characterized by a neutrophil burden. Thus, DNA has been recovered in sputum samples from patients with chronic bronchitis, bronchiectasia, or asthma (38) . This is believed to be due to the fact that when short-lived neutrophils die, they not only release their granule serine proteinases but also their nuclear content. Data obtained with the present experimental model are in agreement with this hypothesis. Indeed, there is a close correlation between the density of neutrophils and the presence of the DNA anti-elastase barrier. However, this is in itself fascinating since it is generally assumed that the present experimental approach generates acute lung inflammation rather than acute lung injury. It is indeed believed that in the present model neutrophils become apoptotic and are eliminated upon phagocytosis by alveolar macrophages, a "silent" nonphlogistic process with an absence of release of nucleic material (39, 40) . It may therefore be hypothesized that a certain proportion of apoptotic neutrophils are not phagocytosed and become necrotic, thereby releasing their content.
The inhibitory effect of biological fluids DNA on proteolytic enzymes has been known for quite a long time (41) . As far as neutrophil elastase is concerned, it has been demonstrated that as for heparin (42), the polyanionic DNA molecules bind elastase and inhibit its elastolytic activity (36) . Although this binding strongly decreases with ionic strength as for heparin, the inhibition is nonetheless potent at the physiological ionic concentration (36) . It appears that under our experimental conditions elastase binds to DNA materials contained in BALF (see Fig. 6 ). This is supported by experiments performed with HTAB, showing that its addition to BALF largely reduced the anti-elastase activity. As shown by Nadziejko et al. (35) , this cationic detergent competes with elastase to form complexes with the polyanionic DNA, with as a consequence less free DNA and therefore more active elastase. An alternative mechanism in DNA-mediated inhibition of elastase might be an indirect one, by promoting the inhibition of elastase by SLPI (43, 44) . Indeed, the treatment with DNase would inactivate the elastase/SLPI/DNA interactions in peak E1, thereby uncovering the elastase activity. This is however speculative, since another report mentions that DNA binds effectively to SLPI but impairs its functional activity (36) .
The in vivo presence and the role of DNA as a direct inhibitor of elastase (and also cathepsin G) activity is evident under our experimental conditions. This is deduced from ex vivo treatment of BALF and in vivo treatment of mice with DNase. It is of note that a potential indirect effect of DNase through a down-regulation of the α1-PI activity (37) was ruled out. As a consequence, the presence of DNA in the airspaces can be considered as beneficial for the lung, and raises the problem of DNase therapy. Such a therapy has been considered in cystic fibrosis patients with the aim of reducing sputum viscosity. As far as elastase is concerned, a review by Vogelmeier and Döring (45) Presence of a DNA-mediated anti-elastase activity in the BALF of patients suffering from Acute Lung Inflammation.
BALF concentrates from 9 patients suffering from ALI were assessed for their antielastase activity upon pretreatment and not with DNase (200 U/ml for 15 min at 37°C). Activities were quantified against purified human leukocyte elastase as described in Methods, and expressed in arbitrary units. 
